Profile
Michael Soumas focuses his practice on corporate securities matters, including private and public offerings and ongoing compliance with the U.S. securities laws. He draws on his deep industry experience as an in-house counsel at a global investment bank to also advise clients on equity derivatives, margin loans and structured finance, with special emphasis on working with Israeli tech companies with capital markets-focused needs.
Michael advises clients on a wide variety of securities laws and governance matters, including drafting and reviewing annual, periodic and current reports and proxy statements, compliance with SEC/stock exchange rules and board meeting minutes, as well as with respect to day-to-day operational matters, including contract review, covenant compliance and investor communications. Michael works with many Israeli tech companies in a myriad of areas including life sciences, food-tech, pharma and others.
Concentrations
- Public and private offerings
- Pharma, medical service, digital health and other life science
- Israeli practice
- Equity derivatives
- Margin loans
Capabilities
Experience
- Ongoing representation of several NYSE- and Nasdaq-traded public companies.
- Represented an Israeli video technology and image science software company in its initial public offering of ordinary shares.
- Represented an Israeli aerospace company focused on advanced safety systems for commercial drones and urban air mobility aircraft in its initial public offering of ordinary shares.
- Represented an Israeli medical device company that is traded on Nasdaq in its private placement offering of common stock and warrants.
- Represented an Israeli Nasdaq traded clinical-stage biopharmaceutical company in its public offering of ordinary shares and warrants.
- Represented an Israeli deep-tech food company at the forefront of the cultivated meat industry in its public offering of American Depositary Shares and warrants. In addition, represented the client in its registered direct offering and concurrent private placement.
- Represented an Israeli-based regenerative medicine company in connection with its execution of a definitive merger agreement with a New York-based special purpose acquisition company.
- Represented an Israeli clinical-stage specialty pharmaceutical company in its registered direct offerings and concurrent private placements of ordinary shares and warrants on Nasdaq.
- Represented an Israeli technology company engaged in advanced transportation safety solutions in its private placement of American Depositary Shares.
- Represented an Israeli pre-commercial stage biopharmaceutical company in its private placement of American Depositary Shares.
- Represented an Israeli company revolutionizing railway safety and the data-related market in its registered direct offering and concurrent private placement of ordinary shares and warrants.
- Represented a Canadian-based psychedelic pharmaceutical biotech company in its public offering of common shares and warrants. In addition, represented the client in its public offering and uplisting to Nasdaq.
- Represented an Israeli-based biotechnology company in its registered direct offering and concurrent private placement of American Depositary Shares and warrants on the New York Stock Exchange.
- Represented an Israel-based omnichannel e-commerce platform and provider of AI-driven measurement solutions, in its registered direct offering and concurrent private placement of common stock and warrants. In addition, advised the company in repricing of warrants.
- Represented an Israeli medical device company in connection with its execution of a definitive business combination agreement with a leading dental implant company.
- Represented a boutique investment bank on a public offering for a health company that develops and markets clinical & consumer medical-grade health monitoring solutions.
- Vice President and Counsel, Credit Suisse Securities (USA) LLC, 2014-2022
Recognition & Leadership
- Chambers Global
- Team Member, Corporate/M&A (Desk based Abroad in USA), 2022-2024
- LMG Life Sciences EMEA Awards:
- Shortlisted, Israeli Firm of the Year, 2025
- Shortlisted, Corporate Rising Star, 2024
- LegallyIsrael100
- Team Member, Capital Markets, 2023-2025
- Team Member M&A (Volume & Value), 2022-2024
- Team Member, Hi-Tech, 2022-2025
- Team Member, Litigation, 2022-2024
- Team Member, Banking & Finance, 2022-2024
- Dun's 100 (Israel)
- Recognized, Capital Markets, Notable Law Firm, 2025
- Recognized, International Commercial, Prominent Team, 2022-2025
- Recognized, Hi-Tech, Notable Law Firm, 2022-2025
- BDiCode
- Recognized, Commercial, Prominent Leaders, 2022-2023
- Recognized, International Commercial, Prominent Leaders, 2022-2024
- Recognized, Capital Markets, Prominent Leaders, 2024
- Recognized, Hi-Tech, Prominent Leaders, 2021-2024
Credentials
Education
-
J.D., cum laude, New York Law School
- Staff Editor, New York Law School Law Review
- John Marshall Harlan Scholar, affiliated with the Center for Business and Financial Law
- B.A.S., Economics, Pennsylvania State University
Admissions
- New York
^
Attorneys in the Tel Aviv office do not practice Israeli law.